<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194684</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2129</org_study_id>
    <nct_id>NCT04194684</nct_id>
  </id_info>
  <brief_title>Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer</brief_title>
  <official_title>Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer：a Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-arm, open, multi-center clinical study of nab-paclitaxel as the&#xD;
      therapy ER+/HER2- recurrent metastatic breast cancer。&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 28, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Estimated up to 1 year</time_frame>
    <description>Defined as proportion of complete response and partial response according to RECIST 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>CR+PR+SD≥8 weeks</time_frame>
    <description>Defined as proportion of complete response 、partial response and stable disease according to RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Estimated up to 2 year</time_frame>
    <description>Calculated from the time the study drug was first administered to the first confirmation of disease progression or death (whichever occurs first)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Assigned Interventions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.</description>
    <arm_group_label>Assigned Interventions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female, 18 to 70 years old;&#xD;
&#xD;
          2. histologically confirmed recurrent or metastatic breast cancer, ER-positive (&gt; 10%),&#xD;
             HER-2 negative (Definition: immunohistochemical [IHC] 0, 1+, or in situ hybridization&#xD;
             [ISH] negative It is defined as the ratio of HER2 gene copy number to the number of&#xD;
             CEP17 signals is less than 2.0, or for single probe detection, the HER2 gene copy&#xD;
             number is less than 6);&#xD;
&#xD;
          3. After transfer, ≤2 lines and ≥1 line endocrine therapy, and progress;&#xD;
&#xD;
          4. at least one measurable lesion according to RECIST 1.1 ;&#xD;
&#xD;
          5. ECOG score≤2;&#xD;
&#xD;
          6. Expected survival≥3 months;&#xD;
&#xD;
          7. Bone marrow function: white blood cells≥3×109/L, neutrophils≥1.5×109/L, platelets&#xD;
             ≥100×109 / L, hemoglobin≥90g / L;&#xD;
&#xD;
          8. Liver and kidney function: total bilirubin (TBIL) ≤1.5 times the upper limit of normal&#xD;
             value, alanine aminotransferase (ALT), aspartate aminotransferase (AST) are ≤2.5 times&#xD;
             the upper limit of normal value; if due to liver metastasis, the above indicators ≤5&#xD;
             times the upper limit of normal value; serum creatinine (Cr) ≤1.5 times the upper&#xD;
             limit of normal value;&#xD;
&#xD;
          9. taxane adjuvant chemotherapy for more than 1 year;&#xD;
&#xD;
         10. Women of childbearing age have a negative pregnancy test and must agree to take&#xD;
             effective contraceptive measures during the study and within 3 months after the last&#xD;
             dose&#xD;
&#xD;
         11. Sign written informed consent before the test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received chemotherapy after transfer;&#xD;
&#xD;
          2. Patients with congestive heart failure with a grade II or above identified by the New&#xD;
             York Heart Association (NYHA) score;&#xD;
&#xD;
          3. Uncontrolled brain metastases;&#xD;
&#xD;
          4. Severe systemic infections;&#xD;
&#xD;
          5. Peripheral neuropathy of degree II or above within 4 weeks before enrollment, or&#xD;
             patients known to be allergic or intolerant to this drug;&#xD;
&#xD;
          6. Important organ diseases:liver and kidney dysfunction, history of myocardial&#xD;
             infarction, unstable heart disease, chronic active hepatitis, etc .;&#xD;
&#xD;
          7. History of other malignant tumors within 5 years (except cured cervical cancer or skin&#xD;
             basal cell carcinoma);&#xD;
&#xD;
          8. Received other anti-tumor treatments or other experimental drugs within 1 month before&#xD;
             starting treatment;&#xD;
&#xD;
          9. Patients participating in other clinical trials at the same time;&#xD;
&#xD;
         10. Any medical condition in which the investigator considers the patient unsuitable for&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Yuan</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Yuan</last_name>
    <phone>+8613501270834</phone>
    <email>yuanpeng01@hotmail.com</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Peng Yuan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

